Criteria for risk stratification in patients with PV and risk-adapted therapy
| Risk category . | Risk variables . | Therapy . |
|---|---|---|
| Low | Age <60 years old; and no thrombosis history | Phlebotomy and correction of CV risk factors, and aspirin |
| High | Age ≥60 years old and/or thrombosis history | Cytoreduction, and correction of CV risk factors, and aspirin*, plus/minus phlebotomy† |
| Risk category . | Risk variables . | Therapy . |
|---|---|---|
| Low | Age <60 years old; and no thrombosis history | Phlebotomy and correction of CV risk factors, and aspirin |
| High | Age ≥60 years old and/or thrombosis history | Cytoreduction, and correction of CV risk factors, and aspirin*, plus/minus phlebotomy† |
The most frequent thrombosis in PV includes stroke, myocardial infarction, peripheral arterial thrombosis, transient ischemic attack, peripheral vein thrombosis, pulmonary embolism, and thrombosis in unusual venous districts. Aspirin is low-dose, i.e., 81 to 100 mg daily. CV, cardiovascular.
Or, depending on the thrombosis type, oral anticoagulation instead of aspirin.
Phlebotomy may be associated with cytoreductive therapy to, initially, speed up and, later, help to maintain the target level of Hct.